KML Vision and Phoenestra Forge Partnership to Enhance Stem Cell-Based Product Development with AI

KML Vision GmbH, a bioimage analysis software provider, and Phoenestra GmbH, specializing in stem cell bioprocessing, have initiated a collaborative venture.

Together, they aim to leverage the latest Artificial Intelligence (AI) technology for microscopy image analysis in bioprocess optimization and quality assurance, thus advancing the development of innovative stem cell-based products in the life and health sciences.

Advancing Stem Cell Bioprocessing with AI

Induced pluripotent stem cells (iPSCs) offer immense potential for precision medicine. However, achieving controlled and scalable differentiation into target cell lines is crucial for clinical success. To ensure product safety and efficacy, various key performance indicators and quality attributes must be closely monitored.

Phoenestra focuses on creating scalable technology platforms for cell-based products, particularly for drug discovery and cell therapy. In preclinical R&D, collecting and analyzing bioprocessing data is vital to maintain product quality. Microscopy plays a pivotal role in this process, but structured image data analysis requires versatile IT solutions.

KML Vision has developed a software platform that utilizes state-of-the-art AI for specialized image analysis solutions. These AI methods address bioprocess optimization, quality assurance, and the definition of complex products, helping tackle the inherent complexity of biology.

According to Philipp Kainz, CEO of KML Vision, "Developing novel cell-based therapeutics demands rigorous quality assurance of complex biological processes, preferably in a continuous and automated way. Our AI-driven image analysis technology reliably enhances workflows across the value chain and we are looking forward to a fruitful partnership with Phoenestra."

Klaus Graumann, CEO of Phoenestra, states, "We are committed to bringing promising new therapeutic modalities closer to patients. Cell-based therapeutics are among the most complex biopharmaceuticals, requiring new analytical approaches for success. Therefore, we are excited to announce our strategic collaboration with KML Vision, a leader in AI-driven image analysis."

The partnership focuses on custom designing and large-scale production of iPSC-derived products. Together, these companies will advance their platform technologies and accelerate the development of novel cell-based products for drug discovery and therapeutic applications.

Introducing both collaboration partners

About KML Vision

KML Vision develops award-winning microscopy image analysis solutions for the needs of life science research. Powered by the latest Artificial Intelligence technology, their flagship software product, the IKOSA Platform, empowers customers to create their own unique bioimage analysis applications without requiring writing any software code. IKOSA solutions deliver quick, reliable, and reproducible insights into complex life science questions, while supporting more efficiency, flexibility, and precision in research. https://www.kmlvision.com/our-offerings/ikosa-ai/

About Phoenestra

Phoenestra develops innovative technology platforms which enable the scalable manufacturing of stem cell-derived products. Based on a patented cell source (human urine), induced pluripotent stem cell lines are developed in house, while stable telomerized MSC lines (MSC/TERT) are licensed from Evercyte GmbH. Also, Phoenestra currently establishes GMP resources for GMP cell banking and early clinical supplies of cell-derived therapeutic products including Extracellular Vesicles (EV). https://www.phoenestra.com/

KML Vision GmbH
Nikolaiplatz 4,
8020 Graz, Austria
Tel.: +43 680 156 75 96
E-Mail: press@kmlvision.com
Website: https://www.kmlvision.com

KML Vision develops leading bioimage analysis software products powered by AI.

This release was published on openPR.